Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells.

Maxim YankelevichArchana ThakurShakeel ModakRoland ChuJeffrey TaubAlissa MartinDana SchalkAmy SchienshangSarah WhitakerKatie ReaDaniel W LeeQin LiuAnthony F ShieldsNai Kong V CheungLawrence G Lum

Published in: Journal for immunotherapy of cancer (2024)

cells/kg/infusion. Coupled with evidence of post-treatment endogenous immune responses, our findings support further investigation of GD2BATs in larger phase II clinical trials.

Keyphrases

phase ii
clinical trial
open label
immune response
induced apoptosis
phase iii
cell cycle arrest
low dose
double blind
placebo controlled
toll like receptor
cancer therapy
randomized controlled trial
study protocol
signaling pathway
cell proliferation
nk cells